menu
    • menu

    Company profile for Kynexis Therapeutics

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Kynexis is at the forefront of developing precision therapeutics for brain diseases, particularly focusing on cognitive impairment associated with schizophrenia (CIAS). Their approach involves utilizing biomarkers to advance potential first-in-class treatments. By leveraging extensive data, Kynexis aims to identify and stratify patients based on the underlying causal human biology of the disease. The company is targeting KAT-I...
    Kynexis is at the forefront of developing precision therapeutics for brain diseases, particularly focusing on cognitive impairment associated with schizophrenia (CIAS). Their approach involves utilizing biomarkers to advance potential first-in-class treatments. By leveraging extensive data, Kynexis aims to identify and stratify patients based on the underlying causal human biology of the disease. The company is targeting KAT-II, a crucial enzyme in the kynurenine pathway. KYN-5356, their lead candidate, is a first-in-class small molecule known for its potency and high selectivity for KAT-II.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Kynexis TherapeuticsNetherlands1 Flag
    Country
    Country
    Netherlands
    Address
    Address
    Gooimeer 2 35 1411 DC Naarden
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.kynexistx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/kynexis/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/KynexisTx

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Cognision Partners Kynexis for Cognision System in Phase 2
    Cognision Partners Kynexis for Cognision System in Phase 2

    14 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/cognision-announces-partnership-with-kynexis-to-utilize-its-cognision-system-in-a-phase-2-trial-of-kyn-5356-in-subjects-with-schizophrenia-302615793.html

    PR NEWSWIRE
    14 Nov 2025
    Share Share
    Kynexis Announces 1st Patient Dosed in Phase 2 Trial of KYN-5356
    Kynexis Announces 1st Patient Dosed in Phase 2 Trial of KYN-5356

    30 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/30/3158423/0/en/Kynexis-Announces-First-Patient-Dosed-in-Phase-2-Clinical-Trial-of-KYN-5356-for-Cognitive-Impairment-Associated-With-Schizophrenia.html

    GLOBENEWSWIRE
    30 Sep 2025
    Share Share
    Kynexis Announces Results for KYN-5356 in Cognitive Impairment
    Kynexis Announces Results for KYN-5356 in Cognitive Impairment

    17 Dec 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/12/17/2998058/0/en/Kynexis-Announces-Positive-Topline-Results-from-Phase-1-Study-of-KYN-5356-a-Potential-Treatment-for-Cognitive-Impairment-Associated-with-Schizophrenia.html

    GLOBENEWSWIRE
    17 Dec 2024
    Share Share
    Kynexis Appoints SAB For Brain Disease Precision Therapeutics
    Kynexis Appoints SAB For Brain Disease Precision Therapeutics

    29 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/29/2889695/0/en/Kynexis-Appoints-Esteemed-Scientific-Advisory-Board-Members-to-Advance-Precision-Therapeutics-for-Brain-Diseases.html

    GLOBENEWSWIRE
    29 May 2024
    Share Share
    Kynexis Announces Initiation of First-in-Human Phase 1 Study of KYN-5356
    Kynexis Announces Initiation of First-in-Human Phase 1 Study of KYN-5356

    04 Jan 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/01/04/2803801/0/en/Kynexis-Announces-Initiation-of-First-in-Human-Phase-1-Study-of-KYN-5356-a-Potential-Treatment-for-Cognitive-Impairment-Associated-with-Schizophrenia.html

    GLOBENEWSWIRE
    04 Jan 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search